ATREON
LAWSUIT

Jeremy Smith and Health Connect began distributing Atreon's musculoskeletal and soft tissue products in 2020 — without so much as a signed agreement — growing the territory into Atreon's top-ranked distributorship in the country. Smith also invested $250,000 in Atreon through three subscription agreements.

Defendant Ronald Bracken induced Smith to sign an "Amended and Restated Distribution Agreement" — falsely claiming it was simply updating a prior written agreement (which had never existed). The new contract secretly imposed higher prices, broad termination rights, and a non-compete clause. Bracken told Smith it was merely for optics with investors and would change nothing in practice.

Bracken pressured Smith to settle a dispute with a co-distributor, financially weakening him. Ten days after the settlement was signed, Atreon issued a for-cause termination letter — alleging Smith had failed to expand sales and submit a business plan, despite Smith having done both. Atreon did not follow its own contractual termination procedures.

At a Nashville trade show, Bracken acknowledged the termination was a negotiating tactic — a "Trump Move" — to extract better terms from Smith. He promised in writing to withdraw it and negotiate a new agreement. Those promises, like all the others, were broken.

Despite written assurances from Atreon's counsel that orders would be filled, Atreon refused Smith's order for 600 units of Rotium, issued a second baseless termination letter, and flatly refused Health Connect's offer to prepay in full. Smith had no choice but to sue.

Guilmette Henderson filed suit on behalf of Health Connect Life Sciences and Jeremy Smith, asserting eight counts against Atreon, Nanofiber Solutions, Renovoderm, and Ronald Bracken.